28 results
424B5
ZYME
Zymeworks Inc.
3 May 24
Prospectus supplement for primary offering
4:17pm
the diagnostic test performance information used to enroll patients into clinical trials for drug approval. Based on assessment of the performance information … of therapeutic products. Our ability to reach a definitive agreement for a collaboration will depend, among other things, upon our assessment of the strategic
424B5
ZYME
Zymeworks Inc.
3 May 24
Prospectus supplement for primary offering
4:11pm
on assessment of the performance information, the FDA will publish the minimum performance characteristics recommended for similar tests that may … commercialization of therapeutic products. Our ability to reach a definitive agreement for a collaboration will depend, among other things, upon our assessment
S-3ASR
ZYME
Zymeworks Inc.
2 May 24
Automatic shelf registration
4:34pm
of December 31, 2023 and 2022, and for each of the years in the three-year period ended December 31, 2023, and management’s assessment
S-3ASR
ZYME
Zymeworks Inc.
7 Mar 24
Automatic shelf registration
4:46pm
31, 2023 and 2022, and for each of the years in the three-year period ended December 31, 2023, and management’s assessment of the effectiveness
S-3
96hmykjrv4i
6 Mar 24
Shelf registration
5:25pm
8-K
EX-10.1
f8bnez9y8w usfhk
26 Dec 23
Zymeworks Announces $50 Million Private Placement to EcoR1 Capital
8:09am
8-K
93tuv 58xp0
8 Dec 23
Submission of Matters to a Vote of Security Holders
4:15pm
8-K
ypyx0us5 447evlk
2 Jun 23
Other Events
7:48pm
424B5
p43vq hm7cd4eic
8 May 23
Prospectus supplement for primary offering
5:19pm
424B5
w3ua14wdy
8 May 23
Prospectus supplement for primary offering
5:18pm
DEF 14A
1jxdnxcg 1hg
25 Nov 22
Definitive proxy
6:16am
8-K
EX-1.1
jqo ry9eyfm0m98e4sr
9 Nov 22
Entry into a Material Definitive Agreement
4:50pm